On April 15th 2012, the Financial Times reported that Sanofi’s drug Multaq lost reimbursement in France and faced new restrictions in other countries.

An irregular heartbeat — atrial fibrillation — is a strong predictor of cognitive decline and the loss of independence in daily activities in older people at risk of cardiovascular disease.

RIDGEFIELD, Conn., Nov.

LA JOLLA, Calif., June 27, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announces that the data from its completed Phase 2 CUPID clinical study of MYDICAR® for the treatment of advanced heart failure is being published today online in Circulation, an American Heart Association journal.

SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.